Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of CS-7017 and Erlotinib in Subjects With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy

NCT01101334 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT01101334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01101334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of CS-7017 and Erlotinib in Subjects With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2010
Completion date
April 30, 2013
Enrollment
90 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer (nsclc)